Results 41 to 50 of about 15,810 (189)

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

open access: yesCritical Care, 2021
Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
Jean-François Timsit   +14 more
doaj   +1 more source

Comparison of the

open access: yesJournal of Global Antimicrobial Resistance
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook   +3 more
doaj   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

open access: yes, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Nicolau, David P   +9 more
core   +1 more source

Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria

open access: yesJournal of Microbiology, Immunology and Infection, 2019
Background: Complicated urinary tract infection (cUTI) is often associated with drug-resistant pathogens and requires therapy with broad-spectrum antibiotics.
Guan-Jhou Chen   +5 more
doaj   +1 more source

Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion. [PDF]

open access: yesAntimicrob Agents Chemother
Ceftolozane/tazobactam is a key antibiotic for Pseudomonas aeruginosa infections. Our objective was to determine whether continuous infusion (CI) of ceftolozane/tazobactam can achieve aggressive pharmacokinetic/pharmacodynamic (PK/PD) targets that ...
Cojutti PG   +7 more
europepmc   +2 more sources

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

open access: yesBiofilm
Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón   +9 more
doaj   +1 more source

Pharmacokinetics of ceftolozane-tazobactam during prolonged intermittent renal replacement therapy

open access: yes, 2018
Background: Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely.
Regli, Adrian   +8 more
core   +1 more source

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

open access: yesInternational Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom   +9 more
doaj   +1 more source

Activity of Ceftolozane–Tazobactam against Burkholderia pseudomallei [PDF]

open access: yesThe American Journal of Tropical Medicine and Hygiene, 2018
We investigated the in vitro activity of a novel fifth-generation cephalosporin–tazobactam combination, ceftolozane–tazobactam against Burkholderia pseudomallei, the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type ...
Slack, Andrew   +4 more
openaire   +4 more sources

Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia

open access: yes, 2018
Pseudomonas aeruginosa is a common pathogen causing nosocomial infection. In particular, bloodstream infection (BSI) is associated with a high rate of morbidity and mortality.
Henderson, A.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy